Trump Secures Regeneron Deal in Initial Drug Price Negotiations
President Trump has secured a significant drug pricing deal with Regeneron, marking the conclusion of negotiations that aimed to lower costs for medications. This agreement is part of a broader initiative that the White House initiated last year, where 17 deals were sought.
Details of the Regeneron Deal
Under the new terms with Regeneron, the company has agreed to several key commitments:
- Reduction of drug prices for Medicaid beneficiaries.
- Provision of the cholesterol medication Praluent through Trump’s prescribed program, TrumpRx, at a cost of $225.
- An investment of $27 billion in drug development within the United States.
FDA Approval for Innovative Therapy
On the same day as the announcement regarding drug pricing, Regeneron received approval from the Food and Drug Administration (FDA) for its new therapy, Otarmeni. This drug is notably the first gene therapy to gain approval under the agency’s National Priority Voucher program.
Early trials of Otarmeni have shown promising results, offering modest improvements in hearing for individuals affected by a rare form of hearing loss. However, the drug’s development has faced criticism from certain factions within the Deaf community.
In a significant step forward, Regeneron has pledged to provide Otarmeni at no cost to patients across the United States.
